Skull Base Rep 2011; 1(2): 129-132
DOI: 10.1055/s-0031-1284208
© Thieme Medical Publishers

Esthesioneuroblastoma in an HIV-1 Infected Patient: Case Report

Enrico Maria Trecarichi1 , Jacopo Galli2 , Enrica Tamburrini1 , Katleen de Gaetano Donati1 , Giancarlo Scoppettuolo1 , Cesare Colosimo3 , Francesco Pierconti4 , Gaetano Paludetti2 , Mario Tumbarello1
  • 1Institutes of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
  • 2Otolaryngology, Catholic University of the Sacred Heart, Rome, Italy
  • 3Bio-images, and Radiological Sciences, Catholic University of the Sacred Heart, Rome, Italy
  • 4Pathological Anatomy, Catholic University of the Sacred Heart, Rome, Italy
Further Information

Publication History

Publication Date:
22 July 2011 (online)


Esthesioneuroblastoma (ENB) is an uncommon malignant tumor derived from the specialized neuroepithelium of the upper nasal cavity. The largest case series and meta-analyses suggest the combination of surgery and radiotherapy as the gold standard treatment for ENB. However, an increasing number of case series have reported excellent survival and few complications with minimally invasive endoscopic resection (MIER) in conjunction with radiotherapy of EBN in early stages of the disease. In this case report, the authors describe the first case of ENB in a young adult man who was human immunodeficiency virus (HIV)-1 and Hepatitis C virus (HCV) coinfected. The authors discuss all the aspects of this rare disease, focusing on treatment options and prognosis.


  • 1 Dulguerov P, Allal A S, Calcaterra T C. Esthesioneuroblastoma: a meta-analysis and review.  Lancet Oncol. 2001;  2 (11) 683-690
  • 2 Bradley P J, Jones N S, Robertson I. Diagnosis and management of esthesioneuroblastoma.  Curr Opin Otolaryngol Head Neck Surg. 2003;  11 (2) 112-118
  • 3 Diaz Jr E M, Johnigan III R H, Pero C et al.. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.  Head Neck. 2005;  27 (2) 138-149
  • 4 Zafereo M E, Fakhri S, Prayson R et al.. Esthesioneuroblastoma: 25-year experience at a single institution.  Otolaryngol Head Neck Surg. 2008;  138 (4) 452-458
  • 5 Jethanamest D, Morris L G, Sikora A G, Kutler D I. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.  Arch Otolaryngol Head Neck Surg. 2007;  133 (3) 276-280
  • 6 Pantanowitz L, Schlecht H P, Dezube B J. The growing problem of non-AIDS-defining malignancies in HIV.  Curr Opin Oncol. 2006;  18 (5) 469-478
  • 7 Chiao E Y, Krown S E. Update on non-acquired immunodeficiency syndrome-defining malignancies.  Curr Opin Oncol. 2003;  15 (5) 389-397
  • 8 Cheung M C, Pantanowitz L, Dezube B J. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.  Oncologist. 2005;  10 (6) 412-426
  • 9 Burgi A, Brodine S, Wegner S et al.. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.  Cancer. 2005;  104 (7) 1505-1511
  • 10 Gurtsevitch V E. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis.  Biochemistry (Mosc). 2008;  73 (5) 504-513
  • 11 Zignego A L, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview.  World J Gastroenterol. 2007;  13 (17) 2467-2478
  • 12 Foote R L, Morita A, Ebersold M J et al.. Esthesioneuroblastoma: the role of adjuvant radiation therapy.  Int J Radiat Oncol Biol Phys. 1993;  27 (4) 835-842
  • 13 Levine P A, Gallagher R, Cantrell R W. Esthesioneuroblastoma: reflections of a 21-year experience.  Laryngoscope. 1999;  109 (10) 1539-1543

Mario TumbarelloM.D. 

Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore

Largo A. Gemelli 8, 00168 Roma, Italy